Company Overview and News

 
D-Street Buzz: PSU banks drag as BoB falls 2%; Weak rupee helps IT stocks gain led by Mindtree

2018-09-17 moneycontrol
The Indian stock market are trading on a weak note this Monday morning with the Nifty50 down 110 points and is trading at 11,404 while the Sensex is trading lower by 361 points at 37,729.
IOC 500325 500820 500547 533271 RELIANCE TCHQY 532538 ASHOKA 532755 ASIANPAINT 535789 505200 532461 INOXWIND RIGD UCLQY JSL EICHERMOT UNIVCABLES RLNIY 504212 SBAZ ECQRY UBNC BPCL 532508 IDKQY CANFINHOME UCLQF 511196 530965 ULTRACEMCO TECHM IBULHSGFIN PNJZY BRQPY PNB HINDPETRO 500104 539083

 
BPCL shelves Bina Refinery IPO plan

2018-09-17 freepressjournal.in
Mumbai : Bharat Petroleum Corporation (BPCL), which owns Bina Refinery in an equal JV with Oman Oil Company, has shelved its IPO plans for the company as “it generates enough cash” to complete the ongoing expansion and as also “because Kuwaiti Petroleum is keen to pick up a stake”, said an official.
BPCL 500547 BRQPY

 
Bharat Petroleum shelves Bina Refinery IPO plan

2018-09-16 livemint
Mumbai: State-run Bharat Petroleum (BPCL), which owns Bina Refinery in an equal JV with Oman Oil Company, has shelved its IPO plans for the company as “it generates enough cash” to complete the ongoing expansion and as also “because Kuwaiti Petroleum is keen to pick up a stake”, says a senior official.
BPCL 500547 BRQPY

 
Sunday Gyaan! With petrol price set to touch Rs 90 a litre in Mumbai, here’s how to check fuel prices

2018-09-16 freepressjournal.in
Nowadays, before travelling people first check is fuel prices, as petrol and diesel prices are scaling new highs every day on account of rupee depreciation and rise in international oil rates. The petrol price is about to touch Rs 90 in Mumbai. As on September 15, the price was hiked by 35 paise and diesel rates went up by 24 paise. So petrol in Mumbai now (as on September 15) costs Rs 89.01 per litre and diesel is priced at Rs 78.
IOC BPCL 500547 BRQPY 530965

 
India#39;s Iran oil purchases to fade ahead of US sanctions

2018-09-14 moneycontrol
Indian refiners will cut their monthly crude loadings from Iran for September and October by nearly half from earlier this year as New Delhi works to win waivers on the oil export sanctions Washington plans to reimpose on Tehran in November.
IOC 500325 BPCL 500547 RELIANCE 530965 BRQPY RIGD HINDPETRO 500104 500110 CHENNPETRO RLNIY

 
As OMC shares bleed, analysts say correction may be overdone

2018-09-14 livemint
Shares of state-run oil marketing companies have been bleeding as they faced the dual blows of rising crude oil prices and a steep fall in rupee, but analysts argue their current valuations are attractive as the concerns may be overdone.
IOC BPCL 500547 BRQPY HINDPETRO 530965 500104

 
HPCL, BPCL, IOC, Jet Airways, InterGlobe decline over 1% on rising oil prices, weak rupee

2018-09-12 moneycontrol
Shares of the state-run oil marketing companies Indian Oil Corporation (IOC), Hindustan Petroleum Corporation (HPCL) and Bharat Petroleum Corporation (BPCL) fell more than a percent each on rising crude oil prices and sustained volatility in the Indian rupee against the US dollar.
IOC INDIGO BPCL 500547 BRQPY 532617 HINDPETRO JETAIRWAYS 530965 500104 539448

 
BPCL to skip Iran oil purchases in October: Sources

2018-09-11 moneycontrol
India's state-run Bharat Petroleum Corp will skip purchase of Iranian oil in October due to turnaround at its plants, a source privy to the plan said on Tuesday.
BPCL 500547 BRQPY

 
BPCL to skip Iran oil purchases in October: Source

2018-09-11 moneycontrol
India's state-run Bharat Petroleum Corp will skip purchase of Iranian oil in October due to turnaround at its plants, a source privy to the plan said on Tuesday.
BPCL 500547 BRQPY

 
India’s August imports of Iran oil down a third month-on-month

2018-09-06 thehindubusinessline
India imported about 5,23,000 barrels per day (bpd) of oil from Iran in August, down 32 per cent on a month earlier, preliminary tanker arrival data showed, as the United States steps up pressure on buyers to halt Iranian energy imports from November.
500325 BPCL 500547 BRQPY RELIANCE RIGD RLNIY

 
HPCL, BPCL hit 52-week lows on crude oil price surge, IOC falls 1%

2018-09-05 moneycontrol
Shares of oil marketing companies fell over a percent, with HPCL and BPCL hitting fresh 52-week lows, as crude oil prices move upwards. The Brent crude is hovering close to USD 80 per barrel and this has impacted sentiment among investors.
IOC BPCL 500547 BRQPY HINDPETRO 530965 500104

 
Indian Oil, others seek out startups to improve fuel efficiency

2018-09-03 livemint
Mumbai: India’s top state-run fuel retailers are collaborating and often investing in startups to solve several vexing issues facing the companies. For Indian Oil Corp. Ltd, corrosion of its pipelines has been an enduring problem. The country’s largest fuel retailer spends ₹ 70,000 per kilometre annually to maintain its pipeline and with the task of monitoring a 13,000km-long network, the cost of keeping the pipeline network healthy is mammoth.
IOC BPCL 500547 BRQPY HINDPETRO 530965 500104

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

10h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

10h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

12h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...